Author Archives: Giovanni Ciavarra

ToxicoGenomica at the DRI Toxic Torts and Environmental Law Seminar 2025: Tackling the Impediments to Obtaining and Using Genetic Testing in Toxic Tort Cases

| May 15, 2025

Dr. Len Van Zyl of ToxicoGenomica recently joined a distinguished panel at the 2025 Toxic Torts and Environmental Law Seminar, held from March 26-28 in Atlanta. The panel, titled Offense is the Best Defense: Tackling the Impediments to Obtaining and Using Genetic Testing in Toxic Tort Cases, explored the latest scientific studies on genetic causation […]

Free Perrin Webinar on April 10 2025: Updates on BAP1 and BRCA Genes as Causes of Mesothliomas and Other Cancers – Don’t Miss the Latest Developments

| March 21, 2025

Join us for this complimentary CLE webinar on April 10, 2025 from 2:00-3:40 PM ET CLICK HERE TO REGISTER FOR WEBINAR On April 10 at 2pm ET, please join us for Toxicogenomica’s free webinar focused on inherited mutations that cause mesotheliomas and other cancers, independent of asbestos or other toxicants. This webinar will cover important 2024 […]

ToxicoGenomica at Perrin Conference 2023: Not All Tumor Suppressor Genes are Equivalent

| October 27, 2023

ToxicoGenomica recently presented at the National Asbestos Litigation Conference (September 12-13, 2023) hosted by Perrin Conferences and the slides are now available for download. Len van Zyl, Ph.D, and CEO of ArrayXpress participated in an engaging panel moderated by Douglas Sinars, Esq. and titled Medical & Scientific Literature Update on Asbestos & Mesothelioma. The panel […]

2023 Brings Multiple Waves Of Additional Studies Regarding Mesotheliomas And Other Cancers Caused Solely By Genomic Factors

| September 5, 2023

ToxicoGenomica recently presented a webinar organized by Perrin Conferences and the slides are now available for download. The webinar focused on the latest publications, scientific studies, and statistics regarding genomics role in cancers. It also covered predictive software and other tools for understanding the impact of germline mutations on disease development and progression. The speakers […]

Perrin Conferences Presents: 2023 Brings Multiple Waves of Additional Studies Regarding Mesotheliomas and Other Cancers Caused Solely by Genomic Factors

| June 1, 2023

Join us for this complimentary CLE webinar on Tuesday, July 18, 2023 from 2:00-3:30 pm ET. This webinar will focus on the latest publications, scientific studies, and statistics regarding genomics role in cancers. It will also cover predictive software and other tools for understanding the impact of germline mutations on disease development and progression. There […]

Perrin Conferences Presents: Cutting-Edge Issues in Asbestos Litigation

| March 2, 2023

Kirk Hartley of ToxicoGenomica will cover the topic of the continually increasing value of genomic analysis to evaluate mesothelioma causation at the upcoming Perrin Conference on Cutting-Edge Issues in Asbestos Litigation. As part of a panel on genetics and science, Kirk will discuss important new papers with data showing the increasing findings of genomic drivers of mesotheliomas. One portion […]

Key Developments in the Use of Genomics in Mesothelioma Cases: Causal Role of BAP1 Null (Loss of Function) Mutations in Mesothelioma and Key Legal Findings

| December 19, 2022

ToxicoGenomica recently presented a webinar organized by Perrin Conferences and the slides are now available for download. The title of the session was Key Developments: Genomics in Mesothelioma Cases. The webinar focused on the latest cases, the most recent science and publications, and the evolving applications and cost of deployment of the science of genomics […]

Graphical Illustration of the Difference Between Genetic Susceptibility and Predisposition [Slides for Download]

| July 7, 2021

At our recent conference Genomic Analysis in Tort Cases, one of the panels focused primarily on communicating genomic issues to juries and judges, including extensive slides and comments from Magna Legal on communicating the concepts of genetic predisposition and “susceptibility” to cancer, where the defense often seeks to make genetic predisposition arguments and plaintiffs often […]